Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 17/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769823 | 1.00 | EGFR (0.39) | EGFRSOS1KRASERBB2JAK3 | |
| SCHEMBL3536485 | 0.96 | EGFR (0.39) | EGFRSOS1KRASERBB2JAK3 | |
| SCHEMBL3769044 | 0.96 | EGFR (0.39) | EGFRSOS1KRASERBB2JAK3 | |
| SCHEMBL3541445 | 0.94 | SOS1 (0.40) | EGFRSOS1KRASERBB2 | |
| SCHEMBL3762497 | 0.94 | SOS1 (0.40) | EGFRSOS1KRASERBB2 | |
| SCHEMBL18010596 | 0.85 | EGFR (0.41) | EGFRSOS1 | |
| SCHEMBL252518 | 0.82 | EGFR (0.44) | EGFRSOS1ERBB2JAK3ERBB4 | |
| SCHEMBL252517 | 0.82 | EGFR (0.44) | EGFRSOS1ERBB2JAK3ERBB4 | |
| SCHEMBL16225141 | 0.81 | EGFR (0.43) | EGFRSOS1ERBB2JAK3ERBB4 | |
| SCHEMBL16225139 | 0.81 | EGFR (0.43) | EGFRSOS1ERBB2JAK3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8919342-B2 | Inhaler | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| US-20100313886-A1 | INHALER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20080051392-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | KONETZKI INGO | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051392-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | CHRM2, CFTR, TPSB2 | EGFR 2881/4885SOS1 4585/4885KRAS 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.